The fading of the mpox outbreak among men who have sex with

2 men: a mathematical modelling study

- 4 Maria Xiridou¹, Fuminari Miura^{1,2}, Philippe Adam^{3,4}, Eline Op de Coul¹, John de Wit^{3,5},
- 5 Jacco Wallinga¹

1

3

6

15

20

22

- 7 Centre for Infectious Disease Control, National Institute of Public Health and the
- 8 Environment, Bilthoven, the Netherlands
- 9 ² Center for Marine Environmental Studies, Ehime University, Ehime, Japan
- 10 ³ Centre for Social Research in Health, UNSW Sydney, Sydney, NSW, Australia
- ⁴ Institute for Prevention and Social Research, Utrecht, the Netherlands
- ⁵ Interdisciplinary Social Science, Utrecht University, Utrecht, the Netherlands
- 13 ⁶ Department of Biomedical Data Sciences, Leiden University Medical Center (LUMC),
- 14 Leiden, the Netherlands
- 16 Corresponding author: Maria Xiridou, Centre for Infectious Diseases Control, Department
- of Epidemiology and Surveillance, National Institute of Public Health and the Environment,
- 18 PO Box 1, 3720 BA Bilthoven, The Netherlands. Tel: +3130 2743057. Fax: +3130 2744409.
- 19 Email: maria.xiridou@rivm.nl.
- 21 **Counts:** Abstract: 250 words; main text: 3,539 words; tables/figures: 8.
- 23 **Conflicts of interest:** The authors declare that no competing interests exist.
- NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

Funding: The authors received no specific funding for this work. FM acknowledges funding from Japan Society for the Promotion of Science (JSPS KAKENHI, Grant Number 20J00793). **Short title:** Modelling mpox (monkeypox) among MSM. **Keywords:** monkeypox, mpox, men who have sex with men, MSM, mathematical model. Availability of data and materials: The data for the numbers of daily mpox cases in the Netherlands described in this study can be freely and openly accessed on the website of the National Institute of Public Health and the Environment (RIVM) of the Netherlands: https://www.rivm.nl/en/mpox. The data from the "COVID-19, Sex, and Intimacy Survey" and the survey "Monkeypox: a new challenge for your sex life" are third party data and are not freely available; enquiries for data access can be addressed to Prof. J. de Wit at j.dewit@uu.nl. Description and summaries of the data on sexual behaviour from the "COVID-19, Sex, and Intimacy Survey" have been published in Xiridou et al. Sex Transm Diseas 2020; 49:145-153 (https://journals.lww.com/stdjournal/Fulltext/2022/02000/How_the_Disruption in Sexually Transmitted.9.aspx).

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

ABSTRACT Background The mpox (monkeypox) outbreak in the Netherlands started winding down in July 2022, before the mpox vaccination programme was initiated. Most cases were men who have sex with men (MSM). We investigated whether the rapid decline in mpox could be attributed to depletion of susceptible MSM or to behavioural changes. **Methods** We developed a transmission model that was fitted to data on mpox cases in the Netherlands until 25 July 2022, when the mpox vaccination programme started. We included behavioural changes, namely less casual partners and shorter time until mpox cases abstain from sexual contacts. **Results** Without behavioural changes, the peak in modelled mpox cases matched observations, but the decline thereafter was less steep than observed. Allowing for behavioural changes in July 2022, we estimated a 13-24% decline in numbers of casual partners and halving of the infectious time until sexual abstinence. When the vaccination programme started, 64% of MSM with very high sexual activity in the model had been infected. Counterfactual model scenarios reveal that the outbreak could have waned by October 2022 even without the vaccination programme. Import of mpox cases at the end of 2022 could not result in major outbreaks. **Conclusions** The limited size of the mpox outbreak in the Netherlands can be ascribed to the depletion of susceptible MSM with high levels of sexual activity. The subsequent decline was accelerated by behavioural changes in July 2022. Immunity due to infection and vaccination among those most sexually active diminishes the risk of resurgence of mpox.

Introduction

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

Mpox (formerly known as monkeypox) is a zoonotic disease caused by the monkeypox virus (MPXV) [1]. Since May 2022, mpox outbreaks have been reported, mostly among men who have sex with men (MSM) [2, 3]. As of 12 December 2022, 82,628 mpox cases have been confirmed worldwide [2]. The weekly number of cases peaked within 2-3 months in most countries and then declined [2]. Several factors may have contributed to the abrupt decline, including health communication aimed at increasing awareness and behavioural changes in the affected population, increased immunity due to MPXV infection, public health interventions (such as case finding, contact tracing, vaccination), and a decrease in cultural/social events and traveling after the summer of 2022 [3-6]. In the Netherlands, the first mpox diagnosis was on 20 May 2022. The number of mpox cases increased sharply in June 2022, but started declining in the second week of July 2022 [7]. By 31 December 2022, 1,259 cases had been notified [8]. On 25 July 2022, a vaccination programme was initiated, providing smallpox vaccination as pre-exposure prophylaxis to MSM at increased risk to get infected with MPXV [9, 10]. Furthermore, in the second half of June 2022, health communication messages about mpox were disseminated via the media and sexual health intervention platforms for MSM [8, 11-13]. On-site campaigns were also undertaken, providing information about mpox at venues, such as gay bars, sauna's, sex clubs, and festivals [8]. The aim of these activities was to enhance awareness among MSM and to promote sex-positive strategies that reduce the risk to acquire or transmit MPXV, such as reducing the number of sexual partners, choosing partners more selectively, as well as recognizing mpox symptoms, seeking care, and/or abstaining from sex [14]. In an online survey carried out in July and August 2022, participants reported that since the start of the outbreak they had reduced their number of sexual partners (50% of participants), they selected their sex partners more carefully, they avoided visits to gay saunas, sex clubs, and sex parties

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

(66% of participants), and they were willing to refrain from close physical and sexual contacts if they were infected with MPXV [14]. Sex venues and parties in Amsterdam experienced a considerable drop in numbers of visitors in July 2022 [15]. We assessed the contribution of different factors that may have led to the rapid decline in the number of mpox cases. We developed a mathematical model that describes the transmission of MPXV via sexual or intimate contacts among MSM. We fitted the model to data on confirmed daily mpox cases in the Netherlands until 25 July 2022, when the mpox vaccination programme started, because the decline in cases started before this programme. To disentangle the impact of immunity due to infection and the impact of behavioural changes from the impact of vaccination in shaping the course of the outbreak, we examined model scenarios without the vaccination programme until the end of 2022 and investigated whether changes in sexual behaviour or import of infections could trigger new outbreaks. Methods The transmission model We developed a deterministic compartmental model that describes MPXV transmission among MSM (Figure 1). The model parameters are defined in Tables 1-3. We accounted only for transmission via sexual or intimate contacts among main (steady) and casual sex partners. In the model, MSM were divided into four sexual activity groups, based on their number of partners: very low, fairly low, fairly high, and very high sexual activity.

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

The course of mpox infection We conceptualized the course of MPXV infection as follows. After infection, individuals are initially exposed but not yet infectious; later, they become infectious [16-18]. When individuals have symptoms or test positive for MPXV, they may refrain from sexual or intimate activities [18, 19]. In the model, we assumed that infectious individuals may start being sexually abstinent a few days after becoming infectious. Men who are abstinent have a lower probability to transmit MPXV, compared to those who are not abstinent [19]. Most of the infectious individuals recover after a few weeks and become immune, but a small fraction may develop complications and need hospitalization [20, 21]. Vaccinated MSM Smallpox vaccination was ended in the Netherlands in 1974. Based on the fraction of the male population in the Netherlands being born before 1974, in the model we assumed that 25% of MSM in 2022 were vaccinated via the smallpox vaccination programme before 1974 and the vaccine offers some protection against mpox [8]. From the second week of June 2022, close contacts of individuals diagnosed with mpox were offered vaccination with a single dose of third-generation vaccine (Imvanex/Jynneos). To account for these vaccinations, we included in the model a small vaccination rate from 8 June 2022 onwards among those with the highest level of sexual activity. Data We used data on the daily numbers of mpox cases from the national surveillance system for notifiable infectious diseases [8]. The numbers of confirmed mpox cases were ordered according to date of symptom onset, throughout the analyses presented in this study. The

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

earliest date of symptom onset that has been recorded among confirmed mpox cases in the Netherlands was 27 April 2022. Possible behavioural changes in the first three months of the outbreak We examined two possible changes: a decline in the duration of the infectious period while not abstinent and a decline in the number of casual partners [8]. We investigated scenarios where these changes occurred only in July 2022 and scenarios with changes in June and in July 2022. For brevity, these are referred to as behavioural changes in June/July 2022. The magnitude and timing of the changes were obtained from the fitting process. The possibility for changes in July was examined because of the reports of reduced sexual activity and increased awareness [14, 15]. We examined also the possibility of changes in June, because the informative campaigns and the media news about mpox started already in June and may have influenced individuals' behaviour. Model fitting The model was calibrated to the number of mpox cases using a Bayesian approach. We defined uniform prior distributions for the uncertain parameters (Table 1) and sampled 10,000 combinations of parameter values. In a first step, we computed from the model and with each combination of parameter values, the daily number of mpox cases by symptom onset and calculated its Poisson likelihood up to 5 July 2022 (for the scenarios with changes only in July 2022) or up to 17 June 2022 (for the scenarios with changes in June and July 2022) – see Table 3 for the timing of the behavioural changes. This provided us the posterior distributions of all uncertain parameters except those relating to the behavioural changes that occurred in June/July 2022. In a second step, we used the posterior distributions obtained from the first

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

step and fitted the model to data from 5 July or 17 June 2022 until 25 July 2022. The prior distributions of the parameters in the first and the second step are shown in Tables 1 and 3, respectively. The posterior distributions are shown in Tables S1-S3 in the Supplement. Sensitivity analyses for the size of the MSM population Based on the size of the male population [22] and prevalence estimates of same-sex behaviour [23], we assumed that the number of MSM in 2022 was 250,000. Due to uncertainty in those estimates, we repeated the analyses with a population size of 200,000 or 300,000 MSM. Scenarios for the future course of the outbreak We examined hypothetical scenarios for the course of the mpox outbreak until the end of 2022. We undertook model calculations until 31 December 2022 for the scenario without behavioural changes and the scenario with behavioural changes in July 2022. For the latter, we investigated also the impact of modifications that could elicit a resurgence in mpox: Return to pre-mpox levels: From 1 November 2022 onwards, the duration of the infectious period while not abstinent and the number of casual partners were as before the mpox outbreak. Increase in sexual activity: As of 1 November 2022, the duration of the infectious period while not abstinent was as before the outbreak, but the number of casual partners was increased: for each scenario, the reduction A% in number of casual partners that occurred in July 2022 was switched to an increase of 2*A% on 1 November 2022. Import of mpox infections: After 1 November 2022, the duration of the infectious period while not abstinent and the number of casual partners were as before the mpox outbreak and we included import of unvaccinated infectious mpox cases into the group with very

high sexual activity: either a one-time import of 20 cases on 1 November 2022 or a continuous import of 1 case per day from 1 November until 31 December 2022. These are rather worst-case scenarios for the Netherlands, because, after the summer of 2022, the number of confirmed imported mpox cases has been less than 1 case per week.

Results

The decline in the mpox outbreak with and without behavioural changes

Without behavioural changes in the model, the daily number of mpox cases among MSM started declining around 8 July 2022, but the decline was less steep than observed (Figure 2a). The epidemic curve in the overall MSM population paralleled the epidemic curve in the group with very high sexual activity, as the decline in the former started 3-4 days after the decline in the latter had started (Figure 2b). The daily numbers of cases in the other three sexual activity groups were still increasing by 25 July 2022 (Figure 2b). Allowing for behavioural changes in July 2022, we found a decline of 15% (95% credible interval (CrI), 1-29%), 15% (95% CrI, 1-29%), and 23% (95% CrI, 3-30%) in numbers of casual partners of MSM with low, fairly high, and very high sexual activity, respectively, compared to their numbers of casual partners before the mpox outbreak (Table S1 in Supplement). The infectious period while not abstinent was reduced from 7.2 days (95% CrI, 3.8-8.0 days) in May-June 2022 to 3.2 days (95% CrI, 2.1-7.0 days) in July 2022. The timing of these behavioural changes was calculated from the model at 7 July 2022 and there was a rather sharp decline in the number of cases thereafter (Table S1 and Figure 2c,d). Similar levels of decline in the numbers of casual partners were found by allowing for behavioural changes in June and in July 2022 (Table S1). The

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

infectious period while not abstinent was 6.9 days (95% CrI, 3.8-7.9 days) in May 2022, 5.5 days (95% CrI, 2.2-7.9 days) in June 2022, and 3.6 days (95% CrI, 2.1-7.2 days) in July 2022 (Table S1). The changes occurred as of 21 June and 10 July 2022 (Table S1 and Figure 2e,f). Distribution of mpox cases according to level of sexual activity By 25 July 2022, 80% of mpox cases were MSM with very high and 10% with fairly high levels of sexual activity (Figure 3a,b). At that point, 64% (95% CrI, 56-70%) of the group with a very high sexual activity level had been infected with MPXV (Figure 3c), while less than 2% of the other sexual activity groups had been infected with MPXV. In the overall MSM population, 1.1% (95% CrI, 0.9-1.3%) had been infected with MPXV by 25 July 2022. Of all MPXV infections in the model until 25 July 2022, transmission occurred via contacts with casual sex partners in 79% (95% CrI,73-84%) of infections; the infecting partner was a man with very high, fairly high, fairly low, or very low sexual activity in 87.1%, 10.2%, 2.2%, and 0.4% of infections, respectively (Figure 3d). The importance of the size of the MSM population With a smaller population of 200,000 MSM, the modelled decline in the daily number of cases, started earlier, but was less steep, than observed (Figure 4a,b). The number of cases in the very high sexual activity group was lower and peaked earlier (end of June), while the number of cases in the other three sexual activity groups was higher than in the scenario with 250,000 MSM. Among all mpox cases in the model until 25 July 2022, 78% and 11% were MSM with very high and fairly high sexual activity, respectively (Figure 3a). As of 25 July 2022, 74% of the MSM in the very high sexual activity group had been infected with MPXV (Figure 3c). With behavioural changes in June/July 2022, we found a smaller reduction in the

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

infectious period before becoming abstinent, from 6.3 days (95% CrI, 2.8-7.9 days) in May-June 2022 to 4.4 days (95% CrI, 2.1-7.7 days) in July 2022 (Table S2). In a larger population of 300,000 MSM, the outbreak without behavioural changes would have been more severe than what we observed in the data (Figure 4c,d). The number of mpox cases in the model started declining around 15 July 2022, about a week later than observed (Figure 4c). With behavioural changes in the model, the infectious period before becoming abstinent was reduced to less than 3 days in July 2022 (Table S3). As of 25 July 2022, 53% of MSM with a very high sexual activity level had been infected with MPXV (Figure 3c). Without behavioural changes, the total number of mpox cases in the model by 25 July 2022 was 977 (880-1,165); 1,051 (905-1,175); or 1,116 (1,012-1,263) in a population of 200,000; 250,000; or 300,000 MSM, respectively. In the Netherlands, 979 mpox cases had been registered with onset date up to 25 July 2022. *Scenarios for the future course of the outbreak* Without behavioural changes in 2022, the outbreak would have faded out by October 2022 (Figure 5a) and about a month earlier with behavioural changes in July 2022 (Figure 5b). Assuming in the model that, after 1 November 2022, the interval being infectious but not abstinent had the same duration as in May 2022 and the numbers of casual partners were the same as or higher than those before the outbreak, resulted in a negligible increase in the number of cases until 31 December 2022. Import of unvaccinated infectious MSM with very high level of sexual activity resulted in a small increase in mpox cases until 31 December 2022: with a one-time import of 20 cases on 1 November 2022, we found 63 (95% CrI, 50-99) additional mpox cases (Figure 5c), while with a continuous import of one case per day

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

from 1 November to 31 December 2022, we found 114 (95% CrI, 93-166) additional cases (Figure 5d), compared to the scenario without import. **Discussion** We developed a transmission model of the mpox outbreak among MSM and fitted this model to the daily numbers of mpox notifications in the Netherlands. We demonstrated that depletion of susceptibles among MSM with very high levels of sexual activity may have limited further growth of the mpox epidemic, but could not solely account for the rapid decline after the peak. This suggests that behavioural changes may have accelerated the decrease in mpox cases. Furthermore, our findings suggest that, even without the mpox vaccination programme, the level of immunity due to infection among MSM with a very high level of sexual activity was sufficiently high to lead to the fading out of the outbreak by October 2022. Moreover, infection-induced immunity was high enough to impede new outbreaks on the short term even when the levels of sexual activity returned to the pre-mpox levels or new mpox cases were introduced into the population from outside. The major strength of our study is that we quantified the contribution of infection-induced immunity and the contribution of behavioural changes in shaping the outbreak. The model, informed by the daily numbers of registered mpox cases during the rise and the decline of the mpox outbreak, allowed us to explore counterfactual situations and to show that the outbreak could have waned even without interventions of behavioural changes. We incorporated heterogeneity in sexual activity by dividing the population into groups with different levels of sexual activity and captured the assortative mixing of highly active individuals that is characteristic of sexual contact networks. This modelling approach has the

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

advantage of being well established, validated, and extensively studied in the past four decades in the context of several sexually transmitted infections [24-31]. Other modelling approaches, such as stochastic networks and individual-based models, allow for a more detailed simulation of the initial and final phase of the outbreak, with very few infections, but at the cost of parsimony and transparency. Our study is in agreement with the theory developed via earlier studies, showing that heterogeneity in number of sexual partners and assortative mixing enhance the likelihood of occurrence of an epidemic and the rapid spread of an infection, but saturation due to infection-induced immunity in the group with higher than the average sexual activity can lead to low endemic levels (see [24-28] and references herein). Our findings also agree with previous studies on MPXV transmission showing that a very small group of MSM with high level of sexual activity can be sufficient to cause large outbreaks in very short time [32, 33] and a decline in numbers of casual partners could reduce the epidemic size of mpox [5, 33]. Our results correspond well also with a study that showed how the observed decline in mpox cases could be primarily attributed to infection-induced immunity [6]. The present study extends earlier findings as our results quantify the contribution of infection-induced immunity and the contribution of behavioural changes and reveal how these factors shaped the outbreak. In contrast with other studies projecting smaller outbreaks of less than 400 cases [34] or more severe and longer-lasting outbreaks without preventing measures [5, 33, 35], we found that the size of the mpox outbreak was large but self-limited and could have died out within a few months even without behavioural changes or vaccination. We showed that, without behavioural changes, the decline in mpox cases in a larger population of 300,000 MSM started about a week after what we observed in the data. This suggests that the observed decline could be possible only with behavioural changes. Our results suggest that awareness and a reduction in numbers of sexual partners considerably

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

expedited the decline in mpox cases. This demonstrates the importance of accurate and timely communication with populations at risks, without stigmatization or fear-chasing. This is important also for those without mpox symptoms, since there is evidence of asymptomatic or pre-symptomatic mpox infections [36, 37]. In the Netherlands, owners/organisers of sex venues and MSM events collaborated with organisations involved in health promotion for MSM to raise awareness with a sex-positive mindset and based on scientific evidence [15]. This is essential for public health response, since similar outbreaks could occur with other pathogens that are not considered to be sexually transmitted, when introduced into subpopulations with contact levels much higher than the average. Such outbreaks have occurred in the past, for instance, with methicillin-resistant Staphylococcus aureus and hepatitis A virus mong MSM communities [38, 39]. The mpox vaccination programme possibly accelerated the impact of awareness and behavioural changes and offered protection against mpox at the individual level. The programme also reduced the risk of resurgence of mpox, since it enhanced immunity at the population level. Our model can be used to investigate the impact of vaccination and how vaccination can be employed in the long run for some subgroups of MSM. Furthermore, our model could be extended to account for transitioning across sexual activity groups. Our study has important implications for the prevention of mpox outbreaks in the future. Prevention can be achieved by maintaining the current high proportion of immunes in the MSM group with the highest sexual activity level. First, it should be taken into account that this is not a closed fixed group and there may be changes in its consistency over long time periods. For example, MSM with low levels of sexual activity who did not receive vaccination in 2022 might become more sexually active and replenish the pool of susceptible MSM with high level of sexual activity [26], thus making a new mpox outbreak possible. Second, in assessing the effectiveness of public health messages, it is important to consider

the venues that the target group might visit. Having sex in sex clubs and parties has been identified as an independent predictor of MPXV infection [14]. Third, sexual mixing according to age is assortative. The protection from the smallpox vaccine in our analyses is overestimated for MSM less than 45 years and underestimated for MSM older than 45 years. For the current study this has a limited impact, but for future prevention of mpox outbreaks it is important to include the changing distribution of immunity with age.

Conclusion

We demonstrated that depletion of susceptible MSM with high levels of sexual activity as well as behavioural changes accounted for the timing and speed of the decline in mpox cases among MSM in the Netherlands. The level of immunity due to infection within the subgroup of MSM with the highest level of sexual activity was build up so fast that the outbreak could have waned within a few months, even without interventions or behavioural changes. The risk of a resurgence of mpox in the short term seems very low, even with sexual behaviour returning to pre-mpox levels or with import of mpox infections.

Acknowledgements

The authors would like to thank Paul Zantkuijl (Soa Aids Nederland) for information on mpox messages in media and health promotion platforms for MSM in the Netherlands and for information about the reduction in visitors in clubs and sex venues in Amsterdam in July 2022. Anonymous club owners are also thanked for providing the above information. We express our gratitude to the participants, the research teams, and the organizations involved in the "COVID-19, Sex, and Intimacy Survey" and the survey "Monkeypox: a new challenge for your sex life" led by Philippe Adam and John de Wit. Both surveys were conducted in partnership between Utrecht University, the Institute for Prevention and Social Research (IPSR Utrecht), Soa Aids Nederland, and the National Institute of Public Health and Environment (RIVM).

Table 1. Model parameters#

363

Parameter		Value	Source
Duration latent period, days	1/θ	5-8	[16-21, 35, 40, 41]
Days infectious total ^{\$}	$\frac{1}{\gamma} + \frac{1}{\delta}$	14-28	[18-21, 32, 35, 41-43]
Days infectious not-abstinent	1/δ	2-8	[19, 33, 35, 44]
Days infectious abstinent	1/γ		
Probability of transmission per sexual contact	eta_s	0.25-0.40	[16, 33, 42, 45]
Vaccine efficacy for vaccines administered in the past	$1-\sigma_1$	50-65%	Data [¥]
Vaccine efficacy for vaccines administered in 2022	$1-\sigma_2$	80-90%	[1, 18, 19]
Mpox-related death rate	μ_d	0.0004	[46-48]
Factor reducing infectiousness of those vaccinated in the past	v_1	$v_1 = \sigma_1$	
Factor reducing infectiousness of those vaccinated in 2022	v_2	$v_2 = \sigma_2$	
Hospitalization rate	ζ	0.01-0.02	Data [¥] , [47, 49]
% of MSM who were in the past vaccinated against smallpox		25%	[22, 50]
Rate of entry into and exit out of the population*	μ	0.02/year	
Mixing parameter for main partnerships	\mathcal{E}_{M}	0.7-0.9	
Mixing parameter for casual partnerships	$\varepsilon_{\mathcal{C}}$	0.75-0.95	
Vaccination rate, per day**	φ_{ki}	0.0003-0.0005	
Factor reducing transmission from infectious in abstinence	W	0.15-0.7	[19]
Number of MSM in the Netherlands		250,000	[22, 23, 51]
Number casual partners/day, MSM very high sexual activity group		0.7-1.0	Table 2

^{*} Parameters with a range were included in the Latin Hypercube Sampling.

§ The total number of days a mpox case is infectious is the sum of the days being infectious not in sexual abstinence and the days being infectious in abstinence.

* Based on assumption that MSM are sexually active approximately for 50 years.

* Data from the national database of notifiable infectious diseases of the Netherlands [8].

** The vaccination rate is φ_{1i} for uninfected and φ_{2i} for exposed individuals of activity group i. Range of values shown is for fairly high and very high sexual activity groups, from 7 June 2022, chosen such that the weekly number of vaccinations was 0.5-1.5 times the weekly number of cases, assuming that in this period approximately one contact of each diagnosed case was vaccinated. The vaccination rate for the low activity groups was zero throughout the calculations.

Table 2. Parameters that depend on the sexual activity group of individuals.

	Activity group			
	Very	Fairly	Fairly	Very
Parameter for activity group i	low	low	high	high
% in specific activity group*	45.1%	36.4%	17.7%	0.7%
Rate of forming main partnerships per year* (α_{Mi})	0.1	0.2	0.7	0.7
Number of sex contacts per main partner per day (u_i)	0.03	0.06	0.14	0.14
% with main partner* (q_i)	60%	51%	54%	42%
Number of casual partners per day* (α_{ci})	0.006	0.044	0.139	0.7-1.0

^{*} Parameters estimated from data from the first round of the "COVID-19, Sex, and Intimacy Survey" [30]. We used only data from the questions relating to sexual activity in the second half of 2019 (before the start of the pandemic in the Netherlands). Men in the very high sexual activity group reported more than 100 partners in the second half of 2019.

Table 3. Prior distributions of uncertain parameters relating to the changes in behaviour of MSM that may have occurred in June/July 2022. Values were sampled from the uniform distribution with the ranges shown in this table.

	Days infectious	Reduction* in number casual partners of group				
	not-abstinent	Low**	Fairly high	Very high		
	Scenario with	changes at one	e time point:			
After T ₂	2-8	0-30%	0-30%	0-30%		
	Scenario with	changes at two	time points:			
Between T_1 and T_2	2-8	0-30%	0-30%	0-30%		
After T ₂	2-8	0-30%	0-30%	0-30%		
	Dates wh	en changes occ	curred:			
T_1	17-27 June 2022					
T_2	5-15 July 2022					

^{*} It was assumed that the number of casual partners of activity group i was α_{ci} at the beginning of the outbreak (as estimated from the data – see Table 2) and was reduced to $(1 - D_{ij}) * \alpha_{ci}$ after day T_j , with D_{ij} sampled from the uniform distribution between 0 and 0.3. The maximum of 30% reduction was based on preliminary results from the survey "Monkeypox: a new challenge for your sex life" [14] and reports from club owners in Amsterdam who experienced reduced numbers of visitors in July 2022, with the reduction reaching its maximum at the end of July 2022 with approximately 30% less visitors (P. Zantkuijl, personal communication).

**Change applied to both very-low and fairly-low activity groups.

Figure legends

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

Figure 1. Flow diagram of the model for monkeypox virus (MPXV) infections. Individuals in the model are divided into classes according to stage of mpox infection, vaccination status, and whether they are sexually abstinent. Unvaccinated individuals can be susceptible to MPXV (S_{ui}) , exposed to MPXV (E_{ui}) , infectious not sexually abstinent (I_{ui}) , or infectious but sexually abstinent (Y_{ui}) . Individuals vaccinated in the past can be susceptible (S_{vi}) , exposed (E_{vi}) , infectious not abstinent or abstinent (I_{vi}, Y_{vi}) . Individuals vaccinated in 2022 can be susceptible (S_{pi}) , exposed (E_{pi}) , infectious not abstinent or abstinent (I_{pi}, Y_{pi}) . Infectious cases may need hospitalization (H_i) . After recovery, they are immune (R_i) . These classes are further divided into four subclasses according to level of sexual activity. In the model, we accounted for exit out of the population at a per capita rate μ that is not shown in the diagram. Figure 2. The daily number of mpox cases among MSM in the Netherlands from 27 April to 25 July 2022. Black bullets show data from the national database of notifiable diseases of the Netherlands; the other lines were calculated from the model. Mpox cases are shown according to date of symptom onset. Left panels: box-plots of daily number of mpox cases in the overall MSM population. Right panels: median daily number of mpox cases in the overall MSM population (black line), in the groups with high sexual activity level (red lines), and in the groups with low sexual activity level (blue lines). (a), (b) without behavioural changes; (c), (d): with behavioural changes in July 2022; (e), (f): with behavioural changes in June and July 2022. (c)-(f): vertical grey lines show medians (solid lines) and 95% credible intervals (dashed lines) of the day at which the behavioural changes occurred, as obtained from the model fitting. Model results were calculated in a population of 250,000 MSM.

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

Figure 3. The role of subgroups of MSM with different levels of sexual activity, as calculated from the model, for the scenarios with behavioural changes in July 2022. (a) Distribution of cumulative mpox cases until 25 July 2022. (b) Distribution of daily mpox cases. (c) Percent of MSM with very high sexual activity being susceptible to monkeypox virus. (d) Distribution of new monkeypox virus infections among MSM according to the sexual activity group of the infecting individual. In (a), (c) results with population of 200,000; 250,000; or 300,000 MSM; in (b), (d) results with population of 250,000 MSM. Figure 4. The mpox outbreak among MSM in the Netherlands until 25 July 2022, without behavioural changes, assuming a population of (a)-(b) 200,000 MSM or (c)-(d) 300,000 MSM. Data and model results are as explained in Figure 2a-2b. Figure 5. Daily number of mpox cases among MSM in the Netherlands from 27 April to 31 December 2022. Black bullets show data obtained from the national database of notifiable infectious diseases of the Netherlands. Orange box-plots show medians and interquartile ranges calculated from the model in a population of 250,000 MSM. Vertical solid grey lines show the last day of each calendar month. (a) Without behavioural changes. (b) With behavioural changes in July 2022 and continued until 31 December 2022. (c), (d) With behavioural changes in July 2022, but reversed (to their pre-mpox levels) on 1 November 2022; and with import of unvaccinated infectious mpox cases into the group with very high level of sexual activity: (c) import of 20 cases on 1 November 2022, (d) import of 1 case per day from 1 November to 31 December 2022.

References

440

- 441 1. Fine PE, Jezek Z, Grab B, Dixon H. The transmission potential of monkeypox virus in
- 442 human populations. Int J Epidemiol. 1988;17(3):643-50.
- 443 2. WHO. 2022 Mpox (monkeypox) outbreak: global trends, 13 December 2022. 2022
- 444 Accessed 28 December 2022. Available from:
- 445 https://worldhealthorg.shinyapps.io/mpx_global/_w_77b7113a/#section-fns.
- 446 3. European Centre for Disease Prevention and Control. Monkeypox multi-country
- outbreak second update 18 October 2022. 2022 Accessed 28 December 2022. Available
- 448 from: https://www.ecdc.europa.eu/sites/default/files/documents/Monkeypox-multi-country-
- outbreak-second-update.pdf.
- 450 4. Kupferschmidt K. Monkeypox outbreak is ebbing but why exactly? Science, 27
- 451 October 2022.
- 452 5. Brand SPC, Cavallaro M, Hilton J, Guzman-Rincon L, House T, Keeling MJ, et al.
- The role of vaccination and public awareness in medium-term forecasts of monkeypox
- incidence in the United Kingdom. medRxiv, posted August 17, 2022. DOI
- 455 10.1101/2022.08.15.22278788.
- 456 6. Murayama H, Pearson CAB, Abbott S, Miura F, Jung S, Fearon E, et al. Accumulation
- of immunity in heavy-tailed sexual contact networks shapes monkeypox outbreak sizes.
- 458 medRxiv, posted November 15, 2022. DOI 10.1101/2022.11.14.22282286.
- 7. National Institute of Public Health and the Environment (RIVM). Monkeypox, 3
- November 2022. Accessed 26 January 2023. Available from:
- 461 https://www.rivm.nl/en/monkeypox.

- 462 8. van Ewijk C, Miura F, van Rijckevorsel G, de Vries H, Welkers M, van den Berg O, et
- al. Monkeypox outbreak in the Netherlands in 2022: public health response, epidemiological
- and clinical characteristics of the first 1000 cases and protection of the first-generation
- smallpox vaccine. Euro Surveill. In print.
- 9. Dutch Government. Letter to the Dutch Parliament over the monkeypox situation in
- the Netherlands (original title: "Kamerbrief over stand van zaken apenpokkenvirus"), 07 July
- 468 2022. Accessed 26 January 2023. Available from: https://www.rijksoverheid.nl/documenten/
- 469 <u>kamerstukken/2022/07/07/kamerbrief-over-stand-van-zaken-apenpokken.</u>
- 470 10. GGD GHOR Nederland. First regions start with monkeypox vaccination (original title:
- 471 "Eerste regio's starten met vaccinatie monkeypox"), 22 July 2022. Accessed 28 December
- 472 2022. Available from: https://ggdghor.nl/actueel-bericht/eerste-regios-starten-vaccinatie-
- 473 monkeypox/.
- 474 11. Man Tot Man. Do this if you have monkeypox. Updated 19 July 2022. Accessed 28
- 475 December 2022. Available from: https://www.mantotman.nl/en/do-this-if-you-have-
- 476 monkeypox.
- 477 12. NOS Nieuws. In the Netherlands 167 persons diagnosed with monkeypox by now
- 478 (original title: "In Nederland nu bij 167 mensen apenpokkenbesmetting vastgesteld"): NOS;
- 479 2022. Updated 22 June 2022. Accessed 28 December 2022. Available from:
- 480 https://nos.nl/artikel/2433610-in-nederland-nu-bij-167-mensen-apenpokkenbesmetting-
- 481 <u>vastgesteld</u>.
- 482 13. Soa Aids Nederland. Uit de praktijk: 2 plekjes op de eikel, dat is toch geen
- 483 monkeypox? Updated 30 June 2022. Accessed 28 December 2022. Available from:

- https://www.soaaids.nl/nl/professionals/themas/seksoa-magazine/uit-praktijk-2-plekjes-op-
- 485 eikel-dat-is-toch-geen-monkeypox.
- 486 14. Adam PCG, Op de Coul ELM, Bos H, Zantkuijl P, Zuilhof W, Xiridou M, et al.
- 487 Monkeypox-related changes in behaviour among MSM in the Netherlands and their impact on
- 488 the monkeypox outbreak: using behavioural research and theorising to inform the monkeypox
- 489 response. Utrecht University and Institute for Prevention and Social Research, Utrecht, the
- 490 Netherlands; 2022.
- 491 15. Soa Aids Nederland. Samenwerking zorg en horeca onmisbaar in aanpak monkeypox-
- 492 uitbraak. Updated 6 October 2022. Accessed 10 January 2023. Available from:
- 493 https://www.soaaids.nl/nl/professionals/actueel/nieuwsbericht/samenwerking-zorg-horeca-
- 494 onmisbaar-in-aanpak-monkeypox-uitbraak.
- 495 16. Beer E, Rao VB. A systematic review of the epidemiology of human monkeypox
- outbreaks and implications for outbreak strategy. PLoS Negl Trop Dis. 2019;13:e0007791.
- 497 17. Bunge EM, Hoet B, Chen L, Lienert F, Weidenthaler H, Baer LR, et al. The changing
- 498 epidemiology of human monkeypox-A potential threat? A systematic review. PLoS Negl
- 499 Trop Dis. 2022;16(2):e0010141.
- 500 18. World Health Organization. Monkeypox Key Facts, 19 May 2022.
- 501 19. European Centre for Disease Prevention and Control. Considerations for contact
- tracing during the monkeypox outbreak in Europe, 28 June 2022.
- 503 20. Di Giulio DB, Eckburg PB. Human monkeypox: an emerging zoonosis. Lancet Infect
- 504 Dis. 2004;4(1):15-25.

- 505 21. Kaler J, Hussain A, Flores G, Kheiri S, Desrosiers D. Monkeypox: A Comprehensive
- Review of Transmission, Pathogenesis, and Manifestation. Cureus. 2022;14(7):e26531.
- 507 22. Statistics Netherlands. The Netherlands in figures 2022. Accessed 10 January 2023.
- Available from: https://opendata.cbs.nl/#/CBS/en.
- 509 23. Rutgers NISSO Group. Sexual health in the Netherlands. Delft: Eburon; 2006.
- 510 24. Yorke J, Heathcote H, Nold A. Dynamics and control of the transmission of
- 511 gonorrhea. Sexually Transmitted Diseases. 1978;5:51-6.
- 512 25. Hadeler KP, Castillo-Chavez C. A core group model for disease transmission.
- Mathematical Biosciences. 1995;128:41-55.
- 514 26. Anderson RM, May RM. Infectious diseases of humans; dynamics and control. 1st ed
- ed. Oxford: Oxford University Press; 1992.
- 516 27. Garnett GP, Anderson RM. Sexually transmitted diseases and sexual behaviour:
- insights from mathematical models. Journal of Infectious Diseases. 1996;174 (Suppl 2):S150-
- 518 S61.
- 519 28. Hethcote HW, Yorke J. Gonorrhea transmission dynamics and control. Lecture Notes
- 520 in Biomathematics 56. 1984.
- 521 29. Bogaards JA, Mooij SH, Xiridou M, Schim van der Loeff MF. Potential effectiveness
- of prophylactic HPV immunization for men who have sex with men in the Netherlands: A
- 523 multi-model approach. PLoS Med. 2019;16(3):e1002756.
- 30. Xiridou M, Heijne J, Adam P, Op de Coul E, Matser A, de Wit J, et al. How the
- disruption in sexually transmitted infection care due to the COVID-19 pandemic could lead to


- increased sexually transmitted infection transmission among men who have sex with men in
- 527 the Netherlands: a mathematical modeling study. Sex Transm Dis. 2022;49(2):145-53.
- 528 31. Xiridou M, Visser M, Urbanus A, Matser A, van Benthem B, Veldhuijzen I. Ending
- risk-group HBV vaccination for MSM after the introduction of universal infant HBV
- vaccination: a mathematical modelling study. Vaccine. 2021;39(21):2867-75.
- 531 32. Endo A, Murayama H, Abbott S, Ratnayake R, Pearson CAB, Edmunds WJ, et al.
- Heavy-tailed sexual contact networks and the epidemiology of monkeypox outbreak in non-
- endemic regions, May 2022. Online version posted June 13, 2022. medRxiv. DOI
- 534 10.1101/2022.06.13.22276353.
- 535 33. Spicknall IH, Pollock ED, Clay PA, Oster AM, Charniga K, Masters N, et al.
- Modeling the Impact of Sexual Networks in the Transmission of Monkeypox virus Among
- Gay, Bisexual, and Other Men Who Have Sex with Men United States, 2022. MMWR Morb
- 538 Mortal Wkly Rep. 2022;71(35):1131-5.
- 539 34. Bisanzio D, Reithinger R. Keep calm and carry on: projected case burden and duration
- of the 2022 monkeypox outbreak in non-endemic countries. medRxiv. 2022. DOI
- 541 10.1101/2022.05.28.22275721.
- 542 35. Van Dijck C, Hens N, Kenyon C, Tsoumanis A. The roles of unrecognized
- monkeypox cases, contact isolation and vaccination in determining epidemic size in Belgium.
- 544 A modelling study. Clin Infect Dis. 2022.
- 545 36. Miura F, Backer JA, van Rijckevorsel G, Bavalia R, Raven S, Petrignani M, et al.
- Time scales of human mpox transmission in the Netherlands. medRxiv. 2022. DOI
- 547 10.1101/2022.12.03.22283056.

- 548 37. de Baetselier I, van Dijck C, Kenyon C, Coppens J, Michiels J, de Block T, et al.
- Retrospective detection of asymptomatic monkeypox virus infections among male sexual
- health clinic attendees in Belgium. Natur Medicine. 2022;28:2288-92.
- 551 38. Diep B, Chambers H, Graber C, et a. Emergence of multidrug-resistant, community-
- associated, methicillin-resistant *Staphylococcus aureaus* clone USA300 in men who have sex
- with men. Annals of Internal Medicine. 2008.
- 39. Ndumbi P, Freidl G, Williams C, Mardh O, Varela C, Avellón A, et al. Hepatitis A
- outbreak disproportionately affecting men who have sex with men (MSM) in the European
- Union and European Economic Area, June 2016 to May 2017. Euro Surveill.
- 557 2018;23:1700641.
- 558 40. Miura F, van Ewijk CE, Backer JA, Xiridou M, Franz E, Op de Coul E, et al.
- Estimated incubation period for monkeypox cases confirmed in the Netherlands, May 2022.
- 560 Euro Surveill. 2022;27(24).
- 561 41. Peter OJ, Kumar S, Kumari N, Oguntolu FA, Oshinubi K, Musa R. Transmission
- dynamics of Monkeypox virus: a mathematical modelling approach. Model Earth Syst
- 563 Environ. 2021:1-12.
- 564 42. Bankuru SV, Kossol S, Hou W, Mahmoudi P, Rychtář J, Taylor D. A game-theoretic
- model of Monkeypox to assess vaccination strategies. PeerJ. 2020;8:e9272.
- 566 43. Grant R, Nguyen LL, Breban R. Modelling human-to-human transmission of
- 567 monkeypox. Bull World Health Organ. 2020;98(9):638-40.
- 568 44. Brosius I, Van Dijck C, Coppens J, Vandenhove L, Bangwen E, Vanroye F, et al. Pre-
- and asymtpomatic viral shedding in high-risk contacts of monkeypox cases: a prospective

- 570 cohort study. medRxiv, published online 27 November 2022. DOI
- 571 10.1101/2022.11.23.22282505.
- 572 45. Arita I, Jezek Z, Khodakevich L, Ruti K. Human monkeypox: a newly emerged
- orthopoxvirus zoonosis in the tropical rain forests of Africa. Am J Trop Med Hyg.
- 574 1985;34(4):781-9.
- 575 46. Kozlov M. How deadly is monkeypox? What scientists know. Available online
- 576 https://www.nature.com/articles/d41586-022-02931-
- 577 1#:~:text=Out%20of%20more%20than%2057%2C000,over%20the%20past%20few%20deca
- 578 des.2022.
- 579 47. Fink D, Callaby H, Luintel A, Beynon W, Bond H, Lim E, et al. Clinical features and
- management of individuals admtted to hospital with monkeypox and associated complications
- across the UK: a retrospective cohort study. Lancet Infect Dis. Published online: 22
- 582 December 2022. https://doi.org/10.1016/S1473-3099(22)00806-4.
- 583 48. Mailhe M, Beaumont A-L, Thy M, Le Pluart D, Perrineau S, Houhou-Fidouh N, et al.
- Clinical characteristics of ambulatory and hospitalized patients with monkeypox virus
- infection: an observational cohort study. Clin Microbiol Inf. 2022, in print.
- 586 49. DeWitt M, Polk C, Williamson J, Shetty A, Passaretti C, McNeil C, et al. Global
- monkeypox case hospitalisation rates: a rapid systematic review and meta-analysis.
- 588 eClinicalMed. 2022;54:101710.
- 589 50. National Institute of Public Health and the Environment (RIVM). Online National
- 590 System of Registration of Infectious Diseases (OSIRIS): National Institute of Public Health
- and the Environment (RIVM). Available from: https://www.rivm.nl/sniv/handleiding-osiris.

- 592 51. Op de Coul EL, Schreuder I, Conti S, van Sighem A, Xiridou M, Van Veen MG, et al.
- 593 Changing Patterns of Undiagnosed HIV Infection in the Netherlands: Who Benefits Most
- from Intensified HIV Test and Treat Policies? PLoS One. 2015;10(7):e0133232.

FIGURE 1








FIGURE 3








FIGURE 5

